Pharmafit Provence

Alfasigma France

CALCIPRAT 500 mg lozenge Bottle/60

CIP / EAN code: 3400933877262

Product information from VIDAL.

Read the product information
Back to the catalogue

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
Update of 03/12/2025

CALCIPRAT®
calcium


Forms and presentations

Chewable tablet at 500 mg (white):  Bottle of 60.
Chewable tablet at 1000 mg (white):  Bottle of 30.


Composition

  per tablet
Calcium 
500 mg
or 1000 mg
(as carbonate: 1,25 g/tab 500 mg; 2,5 g/tab 1000 mg)
Excipients (common): xylitol, povidone (K 30), lactose monohydrate, aspartame, levomenthol, mint flavour (peppermint essential oil, gum arabic, maltodextrin, sorbitol), talc, magnesium stearate. Excipients with known effect: aspartame, lactose, sorbitol (contained in the flavouring).


Indications

All dosages:
Adjunctive treatment of osteoporosis (senile, postmenopausal, under corticosteroid therapy, due to immobilisation, upon resumption of mobility) (see Contraindications).
Tablet at 500 mg:
Calcium deficiencies, notably during the growth period in children, during pregnancy, and during breastfeeding.
Tablet at 1000 mg:
Calcium deficiencies, notably during the growth period in children over 10 years, during pregnancy and breastfeeding.

Dosage and administration

Oral use.

The tablets are to be sucked.

Adults:
General calcium deficiencies and adjunctive treatment of osteoporosis: 1 to 1,5 g per day, i.e. 2 to 3 tablets at 500 mg or 1 tablet at 1000 mg, per day.
Child:
Calcium deficiencies during growth periods: 500 mg to 1 g per day, i.e. on average 1 to 2 tablets of 500 mg or, in children over 10 years, 1 tablet of 1000 mg, per day.

Contraindications

  • Hypersensitivity to any of the constituents.
  • Hypercalcaemia, hypercalciuria, calcium lithiasis, tissue calcifications (nephrocalcinosis...).
  • Prolonged immobilisations accompanied by hypercalciuria and/or hypercalcaemia: calcium treatment should only be used when mobilisation resumes.
  • Due to the presence of aspartame, phenylketonuria.

Warnings and precautions


Warnings:
  • In cases of renal insufficiency, regularly monitor serum calcium and urinary calcium and avoid administering high doses.
  • Concomitant administration of calcium and vitamin D must be carried out under strict medical supervision (see Interactions).
  • This medicinal product contains terpene derivatives, as excipients, which may lower the epileptogenic threshold. At excessive doses, risk of neurological accidents of the convulsion type in infants and children. Observe the recommended dosages and duration of treatment.
  • This medicinal product contains lactose. Its use is not recommended in patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome (rare hereditary disorders).
  • This medicine contains sorbitol. Its use is not recommended in patients with fructose intolerance (a rare hereditary disease).
Precautions for use
  • In cases of long-term treatment and/or renal insufficiency: it is necessary to monitor urinary calcium and to reduce or temporarily interrupt treatment if it exceeds 7,5 mmol/24 h (300 mg/24 h) in adults, 0,12 to 0,15 mmol/kg/24 h (5 to 6 mg/kg/24 h) in children.
  • In cases of concomitant treatment with cardiac glycosides, tetracyclines, vitamin D, sodium fluoride, bisphosphonate: see Interactions.
  • In cases of a history of epilepsy, take into account the presence of terpene derivatives as excipients.

Interactions

Associations subject to precautions for use:
  • In cases of treatment with cardiac glycosides: oral administration of calcium, especially when combined with vitamin D, increases the toxicity of cardiac glycosides, with risk of serious rhythm disturbances.
    Strict electrocardiographic monitoring as well as serum calcium monitoring.
  • In cases of oral treatment with tetracyclines: it is recommended to space calcium intake by at least 3 hours (possible interference with tetracycline absorption).
  • In cases of association with high doses of vitamin D: weekly monitoring of urinary calcium and serum calcium is essential.
  • In cases of concomitant treatment with a bisphosphonate or with sodium fluoride: it is advised to take calcium 2 hours before either of these therapies, so as not to alter their absorption.
Associations to be taken into account:
  • In cases of treatment with thiazide diuretics: there is a risk of hypercalcaemia due to decreased urinary calcium excretion.

Fertility, pregnancy and breastfeeding

During pregnancy, the daily calcium dose must not exceed 1500 mg.

During breastfeeding, it is preferable not to use this medicine due to:

  • the absence of kinetic data on the passage of terpene derivatives into milk,
  • and their potential neurological toxicity in infants.

Adverse effects

  • Possible digestive disorders such as constipation, flatulence, eructation, nausea.
  • Hypercalciuria, hypercalcaemia in case of prolonged treatment at high doses.
  • Risk of hypophosphatemia.
  • Due to the presence, as excipients, of terpene derivatives and in case of non-compliance with the recommended doses :
    • risk of convulsions in infants and in children;
    • possibility of agitation and confusion in elderly subjects.
Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.


Overdose

  • Symptoms: thirst, polyuria, polydipsia, nausea, vomiting, dehydration, arterial hypertension, vasomotor disorders, constipation. In infants and children, cessation of staturo-ponderal growth may precede all signs.
  • Treatment: stop any calcium and vitamin D intake, rehydration and, depending on the severity of the poisoning, use of diuretics, corticosteroids, calcitonin, peritoneal dialysis, alone or in combination.

Pharmacodynamics

Pharmacotherapeutic class: calcium/mineral element (A: alimentary tract and metabolism).

The high calcium concentration in each intake unit facilitates absorption of a sufficient quantity of calcium, with a limited number of intakes that can be adjusted according to the indications.


Pharmacokinetics

After oral administration, calcium carbonate is mainly absorbed in the upper part of the intestine at a rate of 30 to 40 % of the ingested dose.

Calcium is eliminated via saliva, bile and pancreatic, intestinal and sweat secretions.

Urinary calcium depends on glomerular filtration and the rate of tubular calcium reabsorption.


Preclinical safety

All studies carried out indicate an absence of toxicity of calcium carbonate in animals, at doses corresponding to the recommended dosage in humans.


Storage conditions

Shelf life
3 years.

No special precautions for storage.


HANDLING/DISPOSAL INSTRUCTIONS

No special requirements.


Prescription, supply and reimbursement

Marketing authorisation (AMM) 3400933877262 (1995, SmPC rev 30.06.2017) 500 mg.
3400933941468 (1995, SmPC rev 30.06.2017) 1000 mg.
   
Price: 5,29 euros (60 tablets at 500 mg).
5,29 euros (30 tablets at 1000 mg).
Reimbursed by Social Security at 65 %. Collective.


ALFASIGMA FRANCE
Bords de Seine 1
3, esplanade du Foncet, 92130 Issy-les-Moulineaux
Tel: 01 45 21 02 69. Fax: 01 41 90 69 76
E-mail: info.fr@alfasigma.com

www.alfasigma.fr

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.